# The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

> **NCT04937413** · EARLY_PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 32 (actual)

## Conditions studied

- Malignant Glioma
- Glioblastoma

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT04937413
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-08
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-10-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937413, "The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04937413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*